newsletter.drugdiscoverytoday.com Report : Visit Site

Technical data of the newsletter.drugdiscoverytoday.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host newsletter.drugdiscoverytoday.com. Currently, hosted in United Kingdom and its service provider is Intuitiv Ltd. .

the related websites

newsletter.co.uk mclarenstore.com realtytimes.com stgregoryspreston.org.uk worldwidewords.org g8xeu.co.uk pe4life.org endosoc.co.za agnesb.co.uk lbcma.org.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/7.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

having trouble viewing this email? view it online here website digital edition registration events contacts rss enews - june 2013 editor's choice leveraging hts traditionally, high-throughput screening (hts) has been employed excessively during early drug discovery to identify compounds binding to a single target of interest. nowadays, we experience the shift in research and development toward modulating agents and, more prominently, on small molecules acting simultaneously on a variety of receptors to remedy an indication or disease of interest. in order to increase the outcome of hts, novel approaches had to be and in fact have been developed. accomplishing these goals may be attended by more detailed considerations of biological pathways and deeper integration with computational resources. more free research articles to download platforms for high-throughput screening of wnt/frizzled antagonists 28 may 2013 signaling cascades initiated by wnt lipoglycoproteins and their receptors of the frizzled family regulate many aspects of animal development and physiology. improper activation of this signaling promotes carcinogenic transformation and metastasis. development of agents blocking the wnt-frizzled signaling is of prime interest for drug discovery. despite certain progress no such agents are as yet brought to the market or even to clinical trials. one reason for these delays might be the use of suboptimal readout assays. more shifting from the single to the multitarget paradigm in drug discovery 28 may 2013 increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach. more the holistic integration of virtual screening in drug discovery 28 may 2013 during the past decade, virtual screening has come of age. in this article, yusuf tanrikulu, bjorn kruger and ewgenij proschak document the evolution and maturation of virtual screening from a rather exotic, stand-alone method toward a versatile hit and lead identification technology. virtual screening campaigns have become fully integrated into drug discovery campaigns, evenly matched and complementary to high-throughput screening (hts) methods. more for a full list of downloads/ white papers, please visit http://www.drugdiscoverytoday.com/downloads/ industry news us phase i study is extended to include systemic delivery of oncolytic virus. virttu biologics limited, a uk biotechnology company with expertise in the field of oncolytic viruses, is pleased to announce at asco that an on-going clinical study in the usa with its oncolytic virus, seprehvir® (hsv1716), in children and young adults with non-cns tumours has received permission from the regulatory authorities to enrol patients to receive intra-venous administration of the virus. more cancer research uk launches trial for potential new drug to block cancer cells’ energy supply cancer research uk’s drug development office (ddo) has launched a new clinical trial of a brand new type of experimental drug to treat a range of cancers. more small molecule could have big impact on cancer dr. jung-mo ahn, associate professor of chemistry at the university of texas at dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer. more new data reinforces clinical importance of independent alzheimer’s risk factor manchester, birmingham & oxford, uk may 2013 – cytox limited, a uk company developing diagnostic and prognostic services for alzheimer’s disease, announces the publication of new data using its blood-based phenotor™ assay technology. the data demonstrate the ability of the phenotor assay technology to assess the functional integrity of the mtor pathway through analysis of lymphocytes and the relationship between this pathway and the development of alzheimer’s disease pathology. the paper, published in acta neuropathologica communications1, supports the development of the assay in the assessment of alzheimer’s disease risk in patients. more events 8th protein kinases in drug discovery conference dates: 08 july 2013 until 09 july 2013 location: westin copley place boston hotel, boston, ma, usa website: http://www.gtcbio.com/component/conference/?file=home&cn;=8th... more academic drug discovery conference 2013 dates: 09 october 2013 until 11 october 2013 location: nashville, tennessee, usa website: http://www.addc2013.com/ more computational aspects of high-throughput screening planning and analysis dates: 14 october 2013 until 16 october 2013 location: embl heidelberg, germany website: http://www.embl.de/training/events/2013/chi13-01/ more for a full list of events and conferences, please visit http://www.drugdiscoverytoday.com/events/ received this from a colleague? sign up for your own regular copy of weekly. this e-mail has been sent to you from elsevier, the boulevard, langford lane, kidlington, oxford ox5 1gb, registered in england with registered number 1982084. you are receiving this e-mail because you are a registered subscriber of . we respect your privacy and do not rent, sell or disclose your personal information to any non-affiliated third party without your consent, except as may be stated in our site's privacy policy: http://www.drugdiscoverytoday.com/legal/privacy/

URL analysis for newsletter.drugdiscoverytoday.com

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: DRUGDISCOVERYTODAY.COM
Registry Domain ID: 22084418_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.safenames.net
Registrar URL: http://www.safenames.net
Updated Date: 2017-04-01T03:48:15Z
Creation Date: 2000-03-10T17:59:27Z
Registrar Registration Expiration Date: 2019-03-10T16:59:27Z
Registrar: Safenames Ltd
Registrar IANA ID: 447
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +44.1908200022
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Registry Registrant ID: Not Available From Registry
Registrant Name: Domain Manager
Registrant Organisation: Elsevier Ltd
Registrant Street: The Boulevard
Registrant Street: Langford Lane, Kidlington
Registrant City: Oxfordshire
Registrant State/Province:
Registrant Postal Code: OX5 1GB
Registrant Country: UK
Registrant Phone: +44.1865843830
Registrant Fax: +44.1865853333
Registrant Email: [email protected]
Registry Admin ID: Not Available From Registry
Admin Name: International Domain Administrator
Admin Organisation: Safenames Ltd
Admin Street: Safenames House, Sunrise Parkway
Admin Street:
Admin City: Milton Keynes
Admin State/Province: Bucks
Admin Postal Code: MK14 6LS
Admin Country: UK
Admin Phone: +44.1908200022
Admin Fax: +44.1908325192
Admin Email: [email protected]
Registry Tech ID: Not Available From Registry
Tech Name: International Domain Tech
Tech Organisation: International Domain Tech
Tech Street: Safenames House, Sunrise Parkway
Tech Street:
Tech City: Milton Keynes
Tech State/Province: Bucks
Tech Postal Code: MK14 6LS
Tech Country: UK
Tech Phone: +44.1908200022
Tech Fax: +44.1908325192
Tech Email: [email protected]
Name Server: NS.ELSEVIER.CO.UK
Name Server: NS0-D.DNS.PIPEX.NET
Name Server: NS1-D.DNS.PIPEX.NET
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-04-01T03:48:15Z <<<

"For more information on Whois status codes, please visit https://icann.org/epp"

Safenames - Experts in Global Domain Management and Online Brand Protection

Domain Registration in over 760 different extensions
Enterprise Domain Management since 1999
Mark Protect™ Online Brand Monitoring and Enforcement
Domain Consulting and Strategy
Domain Name Acquisition
Domain Disputes and Recovery

Visit Safenames at www.safenames.net
+1 703 574 5313 in the US/Canada
+44 1908 200022 in Europe

The Data in the Safenames Registrar WHOIS database is provided by Safenames for
information purposes only, and to assist persons in obtaining information about
or related to a domain name registration record. Safenames does not guarantee
its accuracy. Additionally, the data may not reflect updates to billing
contact information.

By submitting a WHOIS query, you agree to use this Data only for lawful purposes
and that under no circumstances will you use this Data to:

(1) allow, enable, or otherwise support the transmission of mass unsolicited,
commercial advertising or solicitations via e-mail, telephone, or facsimile; or
(2) enable high volume, automated, electronic processes that apply to Safenames
(or its computer systems). The compilation, repackaging, dissemination or
other use of this Data is expressly prohibited without the prior written
consent of Safenames. Safenames reserves the right to terminate your access to
the Safenames Registrar WHOIS database in its sole discretion, including
without limitation, for excessive querying of the WHOIS database or for failure
to otherwise abide by this policy. Safenames reserves the right to modify
these terms at any time. By submitting this query, you agree to abide by this
policy.



  REGISTRAR SAFENAMES LTD

  REFERRER http://www.safenames.net

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =drugdiscoverytoday.com

  PORT 43

  SERVER whois.safenames.net

  ARGS drugdiscoverytoday.com

  PORT 43

  TYPE domain

DOMAIN

  NAME drugdiscoverytoday.com

NSERVER

  NS.ELSEVIER.CO.UK 193.131.222.35

  NS0-D.DNS.PIPEX.NET 158.43.129.68

  NS1-D.DNS.PIPEX.NET 158.43.193.68

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2017-04-01

  CREATED 2000-03-10

  EXPIRES 2019-03-10

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .